Cargando…

Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter

As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gongwei, Liu, Ying, Liu, Shuoru, Lin, Yuan, Hu, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603894/
https://www.ncbi.nlm.nih.gov/pubmed/36293504
http://dx.doi.org/10.3390/ijms232012647
_version_ 1784817671219445760
author Wang, Gongwei
Liu, Ying
Liu, Shuoru
Lin, Yuan
Hu, Cheng
author_facet Wang, Gongwei
Liu, Ying
Liu, Shuoru
Lin, Yuan
Hu, Cheng
author_sort Wang, Gongwei
collection PubMed
description As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. However, as the cancer progresses, the effectiveness of treatment options gradually decreases, especially in metastatic castration-resistant prostate cancer (mCRPC), for which there are fewer therapeutic options and which have a shorter survival period and worse prognosis. For this reason, oncolytic viral therapy (PV), with its exceptional properties of selective tumor killing, relatively good safety in humans, and potential for transgenic delivery, has attracted increasing attention as a new form of anti-tumor strategy for PCa. There is growing evidence that OV not only kills tumor cells directly by lysis but can also activate anticancer immunity by acting on the tumor microenvironment (TME), thereby preventing tumor growth. In fact, evidence of the efficacy of this strategy has been observed since the late 19th century. However, subsequently, interest waned. The renewed interest in this therapy was due to advances in biotechnological methods and innovations at the end of the 20th century, which was also the beginning of PCa therapy with OV. Moreover, in combination with chemotherapy, radiotherapy, gene therapy or immunotherapy, OV viruses can have a wide range of applications and can provide an effective therapeutic result in the treatment of PCa.
format Online
Article
Text
id pubmed-9603894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96038942022-10-27 Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter Wang, Gongwei Liu, Ying Liu, Shuoru Lin, Yuan Hu, Cheng Int J Mol Sci Review As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. However, as the cancer progresses, the effectiveness of treatment options gradually decreases, especially in metastatic castration-resistant prostate cancer (mCRPC), for which there are fewer therapeutic options and which have a shorter survival period and worse prognosis. For this reason, oncolytic viral therapy (PV), with its exceptional properties of selective tumor killing, relatively good safety in humans, and potential for transgenic delivery, has attracted increasing attention as a new form of anti-tumor strategy for PCa. There is growing evidence that OV not only kills tumor cells directly by lysis but can also activate anticancer immunity by acting on the tumor microenvironment (TME), thereby preventing tumor growth. In fact, evidence of the efficacy of this strategy has been observed since the late 19th century. However, subsequently, interest waned. The renewed interest in this therapy was due to advances in biotechnological methods and innovations at the end of the 20th century, which was also the beginning of PCa therapy with OV. Moreover, in combination with chemotherapy, radiotherapy, gene therapy or immunotherapy, OV viruses can have a wide range of applications and can provide an effective therapeutic result in the treatment of PCa. MDPI 2022-10-21 /pmc/articles/PMC9603894/ /pubmed/36293504 http://dx.doi.org/10.3390/ijms232012647 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Gongwei
Liu, Ying
Liu, Shuoru
Lin, Yuan
Hu, Cheng
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title_full Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title_fullStr Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title_full_unstemmed Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title_short Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
title_sort oncolyic virotherapy for prostate cancer: lighting a fire in winter
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603894/
https://www.ncbi.nlm.nih.gov/pubmed/36293504
http://dx.doi.org/10.3390/ijms232012647
work_keys_str_mv AT wanggongwei oncolyicvirotherapyforprostatecancerlightingafireinwinter
AT liuying oncolyicvirotherapyforprostatecancerlightingafireinwinter
AT liushuoru oncolyicvirotherapyforprostatecancerlightingafireinwinter
AT linyuan oncolyicvirotherapyforprostatecancerlightingafireinwinter
AT hucheng oncolyicvirotherapyforprostatecancerlightingafireinwinter